Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 5/20 | 0.62 |
| ▸ | GLP1R | P43220 | 9/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.57 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.56 |
| ▸ | CCKAR | P32238 | 1/20 | 0.56 |
| ▸ | CCKBR | P32239 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 1/20 | 0.56 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389186 | 1.00 | IL23R (0.62) | IL23RGLP1RKEAP1C5AR1PTH1R | |
| SCHEMBL29410268 | 1.00 | IL23R (0.62) | IL23RGLP1RKEAP1C5AR1PTH1R | |
| SCHEMBL29389409 | 0.98 | IL23R (0.64) | IL23RKEAP1PTH1RCCKARCCKBR | |
| SCHEMBL29534029 | 0.98 | IL23R (0.61) | IL23RGLP1RKEAP1C5AR1PTH1R | |
| SCHEMBL30037407 | 0.97 | IL23R (0.61) | IL23RGLP1RKEAP1C5AR1PTH1R | |
| SCHEMBL29581449 | 0.94 | GLP1R (0.66) | IL23RGLP1RECE1MUS81 | |
| SCHEMBL29533546 | 0.93 | C5AR1 (0.63) | IL23RGLP1RKEAP1C5AR1PTH1R | |
| SCHEMBL29534240 | 0.93 | C5AR1 (0.63) | IL23RGLP1RKEAP1C5AR1PTH1R | |
| SCHEMBL29533850 | 0.93 | C5AR1 (0.63) | IL23RGLP1RKEAP1C5AR1PTH1R | |
| SCHEMBL29533859 | 0.93 | C5AR1 (0.63) | IL23RGLP1RKEAP1C5AR1PTH1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240287154-A1 | MC3R AGONIST PEPTIDES | COURAGE THERAPEUTICS, INC. | 2024-08-29 | — | — | US | claimed |
| US-20240287154-A1 | MC3R AGONIST PEPTIDES | COURAGE THERAPEUTICS, INC. | 2024-08-29 | — | — | US | disclosed |
| EP-4347019-A1 | MC3R AGONIST PEPTIDES | The Regents Of The University Of Michigan (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022251650-A1 | MC3R AGONIST PEPTIDES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287154-A1 | MC3R AGONIST PEPTIDES | MC3R, MC4R, MC1R | IL23R 466/4885GLP1R 25/4885KEAP1 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.